Browse the evidence

Novel mineralocorticoid receptor antagonists (MRAs) like finerenone reduce cardiovascular events and slow CKD progression in CMS patients with lower hyperkalemia risk compared to traditional MRAs.

If you have kidney disease and heart issues, ask your doctor about finerenone. It protects your kidneys and heart with a lower risk of dangerous potassium levels compared to older drugs. It is taken once daily.

Genetically proxied GIPR agonist reduces the risk of 14 cardiometabolic diseases, including obesity, hypertension, and coronary heart disease, with effects on angina and myocardial infarction partially mediated by the inflammatory biomarker Flt3L.

Genetic evidence supports that activating the GIP receptor reduces the risk of major cardiometabolic diseases, including obesity, hypertension, and heart conditions. This benefit is partly achieved by lowering levels of the inflammatory protein Flt3L, which is linked to angina and heart attacks. This suggests GIP-targeting therapies could offer broader heart health benefits beyond blood sugar control.

Both semaglutide and liraglutide cause gastrointestinal adverse effects (nausea, vomiting, diarrhea) which are the most common reason for drug discontinuation.

Expect gastrointestinal side effects like nausea when starting GLP-1 medications. These are common, usually mild, and tend to decrease over time. Slow titration can help manage them.

Unintentional weight loss is independently associated with increased cardiovascular disease incidence and mortality.

If you are losing weight without trying, see a doctor. It can be a sign of serious health issues that increase your risk of heart disease and death.

In real-world clinical practice, approximately half of patients initiating oral semaglutide for Type 2 Diabetes Mellitus remain on their initial treatment regimen without change for at least 6 months.

If you start oral semaglutide for Type 2 Diabetes, there is a roughly 50% chance you will stay on that exact treatment plan for the next six months without needing to switch or add other diabetes medications. This stability is a common and successful real-world outcome, not a sign that treatment is failing.

GLP-1 and GIP receptor agonists (semaglutide, tirzepatide) are teratogenic in animal models and lack human pregnancy safety data, necessitating discontinuation prior to conception.

Stop semaglutide or tirzepatide 1-2 months before you start trying to get pregnant. While no defects have been reported in humans yet, animal studies show potential risks, so it is safer to be off the medication before conception.

Higher body mass index (BMI) causes structural remodeling of the right ventricle, specifically increasing end-diastolic and end-systolic volumes, independent of left ventricular measures.

Maintaining a healthy BMI is crucial for protecting the structure of your right ventricle. This study shows that higher body weight is causally linked to larger heart volumes, which can lead to dysfunction over time. Weight management strategies, including diet and exercise, can help prevent this structural remodeling.

Standard diagnostic thresholds for natriuretic peptides (BNP/NT-proBNP) are less sensitive in individuals with obesity, potentially missing cases of HFpEF, necessitating adjusted cutoffs or alternative screening scores.

If you have obesity, standard blood tests for heart failure (BNP/NT-proBNP) might not be sensitive enough to detect early problems. Ensure your doctor interprets these results in the context of your weight or uses specialized scoring systems (like the HFpEF-ABA score) that account for obesity.

Over an 8-year period, middle-aged adults of African origin across diverse geographic and socioeconomic settings experienced significant increases in the prevalence and incidence of obesity, high blood glucose, and high blood pressure, with the steepest increases occurring in low- and middle-income countries (Ghana, Jamaica, Seychelles) compared to the USA.

If you are of African descent, your risk for obesity, high blood sugar, and high blood pressure is actively increasing as you age, regardless of whether you live in a wealthy or developing country. The rate of increase is often faster in lower-income settings. This is not inevitable fate but a result of environmental and lifestyle shifts; proactive monitoring and lifestyle interventions are critical to mitigate this rising risk.

Endogenous GLP-1 and GIP hormones play a critical role in cardiovascular physiology, with GLP-1 promoting cardioprotection through anti-apoptotic signaling and improved glucose utilization, while GIP's role is complex and species-dependent.

Your body naturally produces hormones called GLP-1 and GIP that help protect your heart and blood vessels. GLP-1 improves blood flow, reduces inflammation, and helps your heart use energy efficiently during stress. GIP also plays a role in metabolism and heart health. Understanding these natural pathways helps explain why medications that mimic them are so effective for heart health.

GLP-1 receptor agonists (Semaglutide and Tirzepatide) are associated with gastrointestinal adverse effects and specific contraindications, including personal or family history of medullary thyroid cancer.

Be aware that these medications can cause gastrointestinal issues, which are best managed by starting at a low dose and increasing slowly. Do not use these medications if you have a personal or family history of medullary thyroid cancer or Multiple Endocrine Neoplasia type 2.

Tirzepatide (0.144 mg/kg) significantly reduces voluntary alcohol consumption, prevents binge-like drinking, and suppresses relapse-like behaviors in rodents.

Tirzepatide, a dual GLP-1/GIP agonist, significantly reduces alcohol consumption and prevents relapse in rodent models by attenuating dopamine reward signaling. While preclinical, these findings suggest potential for treating Alcohol Use Disorder (AUD) and its metabolic complications.

Tirzepatide improves metabolic and inflammatory markers in alcohol-consuming rodents, including reducing body weight, white adipose tissue, hepatic triglycerides, and pro-inflammatory cytokines.

Tirzepatide improves metabolic health and reduces inflammation in alcohol-consuming rodents, potentially addressing comorbidities of AUD.

Pre-sleep protein supplementation (20g or 60g) does not improve acute muscle recovery (function, soreness, or damage markers) following load carriage in British Army recruits.

If you are doing heavy load carriage (marching with weight), adding extra protein right before bed (20g or 60g) will not speed up your recovery, reduce soreness, or protect your muscle function compared to just eating your normal diet. Focus on getting your total daily protein needs met rather than stressing about pre-sleep dosing for this specific activity.

Supplementing with 30g daily hydrolyzed collagen peptides during intense resistance training does not increase myofibrillar or muscle connective tissue protein synthesis rates compared to placebo.

If you are doing intense resistance training, taking 30g of collagen daily will not make your muscles or connective tissue build protein any faster than if you took a placebo. While collagen does increase specific amino acids in your blood, it does not translate to higher synthesis rates for muscle or connective tissue in this context. Focus on your training and overall protein intake rather than relying on collagen for synthesis stimulation.

Hamstring hypertrophy plays a minimal role in strength transfer between the Nordic hamstring exercise and the stiff-leg deadlift in resistance-untrained individuals.

If you want to improve strength in both Nordic curls and deadlifts, doing only one will not automatically make you strong at the other, even if you build muscle. To maximize strength across both movements, you should train both exercises within the same training block, as neural adaptations specific to each movement pattern are likely more important than muscle size for transferring strength.

Intensive lifestyle interventions (ILI) targeting weight loss and physical activity in older adults (≥70 years) with type 2 diabetes and obesity are associated with increased odds of severe mobility disability compared to diabetes support and education (DSE).

For adults over 70 with type 2 diabetes, aggressive weight loss programs may increase the risk of severe mobility disability compared to standard diabetes education. Focus should shift towards preserving functional status and muscle mass rather than prioritizing significant weight reduction, as the loss of lean mass can outweigh the benefits of fat loss for mobility in this age group.

Higher BMI (Class 2+ obesity, ≥35 kg/m2) is consistently associated with increased odds of mobility, severe mobility, and IADL disability in older adults with type 2 diabetes, regardless of intervention group.

Maintaining a BMI below 35 kg/m2 is crucial for preserving mobility and independence in older adults with type 2 diabetes. While moderate weight loss might not be the primary goal for everyone, avoiding Class 2+ obesity (BMI ≥35) is strongly associated with lower risks of severe mobility and instrumental activities of daily living (IADL) disability.

Endoscopic gastric plication (POSE procedure) produces modest, statistically significant weight loss (approx. 4.9% at 1 year) superior to sham, but remains significantly less effective than bariatric surgery and comparable to pharmacotherapy.

Endoscopic gastric plication is a valid option for Class I-II obesity if you want something more effective than lifestyle changes alone but less invasive than surgery. Expect about 5% weight loss at one year, which is similar to taking weight-loss drugs. It is a one-time procedure but may need repeating as the stomach remodels. Discuss the $11,000 cost and potential risks (like infection) with your doctor, and weigh them against the long-term cost of managing obesity-related conditions.

Stronger corporate nutrition-related commitments in the French food industry do not translate into better product portfolio healthiness or marketing practices.

Do not rely on a company's stated 'health goals' or 'commitments' as a proxy for product quality. The data shows these promises do not correlate with the actual nutritional content of their products. Focus on the product itself (e.g., Nutri-Score, ingredient list) rather than the company's public relations.

Increasing the price of meat, dairy, and oils/fats reduces saturated fat intake, but the demand is inelastic, meaning substantial price increases (e.g., 100% tax) are required to achieve modest reductions in intake.

If you are a policymaker, know that simply raising prices on fats will not drastically change diets because people are not very sensitive to price changes for these items. You would need extremely high taxes (doubling the price) to see any real drop in saturated fat intake, and even then, the drop is small. Focus on meat taxes in high-income countries where sensitivity is higher, but expect limited results overall.

Adopting a restricted carbohydrate diet defined as less than 45% of total energy intake does not significantly alter the risk of all-cause, cardiovascular disease (CVD), or cardiometabolic disease (CMD) mortality compared to consuming 45-65% of energy from carbohydrates.

If you choose to eat a diet where less than 45% of your calories come from carbohydrates, current large-scale data suggests this will not increase your risk of dying from heart disease, metabolic disease, or any other cause compared to eating the standard recommended amount (45-65%). You do not need to fear moderate carbohydrate restriction regarding mortality risk, provided you maintain a balanced intake of fats.

Hospital normal diet meals in public North West province hospitals frequently fail to meet Recommended Dietary Intakes (RDIs) for key micronutrients, specifically folate, vitamin A, and vitamin B6, while often exceeding RDIs for energy, protein, carbohydrates, and fat.

If you are a patient in a public hospital, do not assume the standard 'normal diet' meets all your nutritional needs. The study shows these meals often lack essential vitamins (A, B6, Folate) even if they provide enough calories. Discuss your specific nutritional needs with a dietician or hospital manager, as portion control and menu planning are critical factors in preventing malnutrition and supporting recovery.

Food Frequency Questionnaires (FFQs) used in the PURE study likely overestimate carbohydrate intake and underestimate fat intake in Chinese populations due to the exclusion of edible oils from fat calculations.

When tracking your diet, do not forget to include cooking oils in your fat intake. Self-reported diets often miss these 'invisible' fats, leading to an overestimation of carbohydrate consumption.